The origins of our blood may not be quite what we thought. Using cellular “barcoding” in mice, a groundbreaking study finds that blood cells originate not from one type of mother cell, but two, with potential implications for blood cancers, bone marrow transplant, and immunology. Fernando Camargo, PhD, of the Stem Cell Program at Boston Children’s Hospital led the study, published in Nature on June 15.
“Historically, people have believed that most of our blood comes from a very small number of cells that eventually become blood stem cells, also known as hematopoietic stem cells,” says Camargo, who is also a member of the Harvard Stem Cell Institute and a professor at Harvard University. “We were surprised to find another group of progenitor cells that do not come from stem cells. They make most of the blood in foetal life until young adulthood,
and then gradually start decreasing.”
The researchers are now following up to see if the findings also apply to humans. If so, these cells, known as embryonic multi-potent progenitor cells (eMPPs), could potentially inform new treatments for boosting ageing people’s immune systems. They could also shed new light on blood cancers, especially those in children, and help make bone marrow transplants more effective.
Camargo’s team applied a barcoding technique they developed several years ago. Using either an enzyme known as transposase or CRISPR gene editing, they inserted unique genetic sequences into embryonic mouse cells in such a way that all the cells descended from them also carried those sequences. This enabled the team to track the emergence of all the different types of blood cells and where they came from, all the way to adulthood.
“Previously, people didn’t have these tools,” says Camargo. “Also, the idea that stem cells give rise to all the blood cells was so embedded in the field that no one attempted to question it. By tracking what happened in mice over time, we were able to see new biology.”
Through barcoding, the researchers found that eMPPs, as compared with blood stem cells, are a more abundant source of most lymphoid cells important to the immune responses, such as B cells and T cells. Camargo believes the decrease in eMPPs that they observed with age may explain why people’s immunity weakens as they get older.
“We’re now trying to understand why these cells peter out in middle age, which could potentially allow us to manipulate them with the goal of rejuvenating the immune system,” says Camargo.
In theory, there could be two approaches: extending the life of eMPP cells, perhaps through growth factors or immune signalling molecules, or treating blood stem cells with gene therapy or other approaches to make them more like eMPPs.
Camargo is also excited about the potential implications for better understanding and treating blood cancers. For example, myeloid leukaemia’s, striking mostly older people, affect myeloid blood cells such as granulocytes and monocytes. Camargo thinks these leukaemias may originate from blood stem cells, and that leukaemias in children, which are mostly lymphoid leukaemias, may originate from eMPPs.
“We are following up to try to understand the consequences of mutations that lead to leukaemia by looking at their effects in both blood stem cells and eMPPs in mice,” he says. “We want to see if the leukaemias that arise from these different cells of origin are different – lymphoid-like or myeloid-like.”
Improving bone marrow transplant?
Additionally, the recognition that there are two types of mother cells in the blood could revolutionize bone marrow transplant.
“When we tried to do bone marrow transplants in mice, we found that the eMPPs didn’t engraft well; they only lasted a few weeks,” says Camargo. “If we could add a few genes to get eMPPs to engraft long term, they could potentially be a better source for a bone marrow transplant. They are more common in younger marrow donors than blood stem cells, and they are primed to produce lymphoid cells, which could lead to better reconstitution of the immune system and fewer infection complications after the graft.”
